个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE ◇ 自然指数

作者：
Beiping Miao[1,2] * ; Zhaoqing Hu[1,3] * ; Riccardo Mezzadra[4,5] * ; Lotte Hoeijmakers[4] * ; Astrid Fauster[6] ; Shangce Du[1,7] ; Zhi Yang[8] ; Melanie Sator-Schmitt[1] ; Helena Engel[1,3] ; Xueshen Li[9] ; Caroline Broderick[5] ; Guangzhi Jin[10] ; Raquel Gomez-Eerland[4] ; Lisette Rozeman[4] ; Xin Lei[11] ; Hitoshi Matsuo[1,3] ; Chen Yang[1,2] ; Ingrid Hofland[12] ; Dennis Peters[12] ; Annegien Broeks[12] ; Elke Laport[1] ; Annika Fitz[1] ; Xiyue Zhao[1,3] ; Mohamed A.A. Mahmoud[1,3] ; Xiujian Ma[7,13] ; Sandrine Sander[14] ; Hai-kun Liu[13] ; Guoliang Cui[15] ; Yu Gan[9] ; Wei Wu[16,17,18,19] ; Yanling Xiao[11] ; Albert J.R. Heck[16,17] ; Wenxian Guan[8] ; Scott W. Lowe[5] ; Hugo M. Horlings[20] ; Cun Wang[2] ; Thijn R. Brummelkamp[6] ; Christian U. Blank[4,21,22] ; Ton N.M. Schumacher[4,23] ; Chong Sun[1] ;
机构： [1]German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg,Germany [2]State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai, China [3]Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany [4]Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, theNetherlands [5]Department of Cancer Biology and Genetics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA [6]Division of Biochemistry, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands [7]Faculty of Medicine, Heidelberg University, 69120 Heidelberg, Germ [8]Department of Gastrointestinal Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing,China [9]Department of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ 07030, USA [10]Department of Interventional Radiology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, No. 1111, Xianxia Road,Shanghai 200336, China [11]Department of Immunology, Leiden University Medical Center (LUMC), Leiden, the Netherlands [12]Core Facility Molecular Pathology & Biobanking, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands [13]German Cancer Research Center (DKFZ) Heidelberg, Division Molecular Neurogenetics, DKFZ-ZMBH Alliance, Im Neuenheimer Feld 280,69120 Heidelberg, Germany [14]German Cancer Research Center (DKFZ) Heidelberg, Division Adaptive Immunity and Lymphoma , Im Neuenheimer Feld 280, 69120Heidelberg, Germany [15]German Cancer Research Center (DKFZ) Heidelberg, Division T Cell Metabolism, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany [16]Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for PharmaceuticalSciences, Padualaan 8, 3584 CH Utrecht, the Netherlands [17]Netherlands Proteomics Centre, Padualaan 8, 3584 CH Utrecht, the Netherlands [18]Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore [19]Department of Pharmacy, National University of Singapore, Singapore 117543, Singapore [20]Department of Pathology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands [21]Department of Medical Oncology, Netherlands Cancer Institute (NKI), Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands [22]Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands [23]Department of Hematology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
出处：
DOI： 10.1016/j.ccell.2023.08.008
ISSN：

摘要：
The dysregulated expression of immune checkpoint molecules enables cancer cells to evade immune destruction. While blockade of inhibitory immune checkpoints like PD-L1 forms the basis of current cancer immunotherapies, a deficiency in costimulatory signals can render these therapies futile. CD58, a costimulatory ligand, plays a crucial role in antitumor immune responses, but the mechanisms controlling its expression remain unclear. Using two systematic approaches, we reveal that CMTM6 positively regulates CD58 expression. Notably, CMTM6 interacts with both CD58 and PD-L1, maintaining the expression of these two immune checkpoint ligands with opposing functions. Functionally, the presence of CMTM6 and CD58 on tumor cells significantly affects T cell-tumor interactions and response to PD-L1-PD-1 blockade. Collectively, these findings provide fundamental insights into CD58 regulation, uncover a shared regulator of stimulatory and inhibitory immune checkpoints, and highlight the importance of tumor-intrinsic CMTM6 and CD58 expression in antitumor immune responses.Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.

语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学 1 区 细胞生物学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 细胞生物学 1 区 肿瘤学
JCR分区：
出版当年[2021]版：
Q1 CELL BIOLOGY Q1 ONCOLOGY
最新[2023]版：
Q1 CELL BIOLOGY Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者：
第一作者机构： [1]German Cancer Research Center (DKFZ) Heidelberg, Division Immune Regulation in Cancer, Im Neuenheimer Feld 280, 69120 Heidelberg,Germany [2]State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School ofMedicine, Shanghai, China
共同第一作者：
通讯作者：
通讯机构： [4]Division of Molecular Oncology & Immunology, Netherlands Cancer Institute, Oncode Institute, Plesmanlaan 121, 1066 CX Amsterdam, theNetherlands [21]Department of Medical Oncology, Netherlands Cancer Institute (NKI), Plesmanlaan 121, 1066 CX Amsterdam, the Netherlands [22]Department of Medical Oncology, Leiden University Medical Centre (LUMC), Leiden, The Netherlands [23]Department of Hematology, Leiden University Medical Center (LUMC), Leiden, the Netherlands
推荐引用方式(GB/T 7714)：
Beiping Miao,Zhaoqing Hu,Riccardo Mezzadra,et al.CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1[J].CANCER CELL.2023,41(10):1817-+.doi:10.1016/j.ccell.2023.08.008.
APA：
Beiping Miao,Zhaoqing Hu,Riccardo Mezzadra,Lotte Hoeijmakers,Astrid Fauster...&Chong Sun.(2023).CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1.CANCER CELL,41,(10)
MLA：
Beiping Miao,et al."CMTM6 shapes antitumor T cell response through modulating protein expression of CD58 and PD-L1".CANCER CELL 41..10(2023):1817-+

资源点击量：21169 今日访问量：0 总访问量：1219 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持：重庆聚合科技有限公司 地址：北京市东城区东交民巷1号(100730)